Istiratumab
Based on 1 Customer Validation
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.45%
- CAS No.: 1509928-04-4
- Masse moléculaire:199.63 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform EGFR
More
Activité biologique
Human IgG1 kappa
Human
IGF1R & ERBB3
Istiratumab (500 nM, 24 h) inhibits AKT activation in response to IGF-1 and HRG costimulation in human pancreatic cancer cell lines[2].
Istiratumab (500 nM, 24 h) inhibits IGF-1- and HRG-induced AKT phosphorylation in pancreatic cancer cells that harbor activating KRAS mutations[2].
Istiratumab (500 nM, 24 h) induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway[2].
Istiratumab (1 μM, 60 min) block activation of the PI3K and MAPK signaling cascades in ovarian cancer cell lines[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AsPC1, BxPC3, Capan2, CFPAC1, etc.
-
Concentration:500 nM
-
Incubation Time:24 h
-
Result:Decreased IGF-1R and/or ErbB3 protein levels in pancreatic cancer cell lines.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa-[scFv-heavy-lambda]2
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1×106 MCF-7 cells labelling ERBB3 (red) with Istiratumab (HY-P99672). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1509928-04-4
-
Appearance Liquid
-
Masse moléculaire 199.63 kDa
-
Color Colorless to light yellow
-
SMILES
[Istiratumab]
-
Synonyms
MM 141; MM-005
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. [Content Brief]
[2]. Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. [Content Brief]
[3]. Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Istiratumab Related Classifications
HY-P99672 Related Classifications
Powered by Bioz